Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a daily spleen zap ease long COVID fatigue?

NCT ID NCT06189066

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed pilot study tested a daily ultrasound device applied to the spleen for 8 weeks in 15 adults with Long COVID. The goal was to see if it safely improves symptoms like fatigue, pain, and brain fog. Researchers measured walking endurance and fatigue levels before and after treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ultrasound device applied to the spleen
What this could lead to
If it works, this could point toward a non-drug way to ease Long COVID symptoms like fatigue and brain fog.
What could go wrong
This was a very small pilot study with only 15 people and no comparison group, so results may not be reliable or apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

15 people

The number who actually took part.

Started

Jan 2024

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18-65 years at the time of enrollment 2. Prior diagnosis of COVID-19 by report, PCR, or home kit 3. Symptoms present for 12 or more weeks that are independent prior to SARS-CoV-2 infection including fatigue and one or more of: 1. Myalgia or general aches/pains 2. Joint pain 3. Dizziness/lightheadedness 4. Cognitive dysfunction (brain fog) Exclusion Criteria: 1. Candidate who is unable or unwilling to postpone taking new medications used for treating Long COVID during the study period 2. Candidate that is currently taking immune modifying medications and unable to maintain stable levels of their immune medication regimen throughout the study period 3. History of intubation secondary to COVID-19 4. ICU admission for COVID-19 5. Pre-existing Lung conditions such as chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), or severe asthma 6. Pregnant 7. History of coronary artery disease (CAD) 8. History of stroke 9. History of severe anemia of hemoglobin less than 8 g/dl 10. Prior history of Lyme disease 11. Prior history cognitive impairment 12. Any non-marijuana drug abuse history within 30 days 13. Current use of an investigational drug 14. History of prior myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS) 15. History of alcohol abuse: greater than 2 drinks a day for men and 1 drink for females 16. Prior history of postural orthostatic tachycardia syndrome (POTS) 17. Chronic fatigue secondary to any condition other than COVID-19. 18. Fibromyalgia 19. History of prior chronic pain 20. History of chronic liver disease such as cirrhosis 21. History of splenic pathology such as spleen infarct/splenomegaly 22. History of splenectomy 23. History of Sickle disease with splenic pathology 24. Taking non-approved treatments for Long COVID 25. Participant does not speak English 26. Participant is an active member of the military (service member) or DoD personnel (including civilian employees) 27. Any other clinical reasons deemed by the investigators of the study in which the patient would not be an appropriate candidate for the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Long COVID are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Minnesota - Phillips-Wangensteen Building

    Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.